NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome

Purpose: Treatment options are limited for patients with high-risk myelodysplastic syndrome (MDS). The azanucleosides, azacitidine and decitabine, are first-line therapy for MDS that induce promoter demethylation and gene expression of the highly immunogenic tumor antigen NY-ESO-1. We demonstrated that patients with acute myeloid leukemia (AML) receiving decitabine exhibit induction of NY-ESO-1 expression in circulating blasts. We hypothesized that vaccinating against NY-ESO-1 in patients with MDS receiving decitabine would capitalize upon induced NY-ESO-1 expression in malignant myeloid cells to provoke an NY-ESO-1–specific MDS-directed cytotoxic T-cell immune response. Experimental Design: In a phase I study, 9 patients with MDS received an HLA-unrestricted NY-ESO-1 vaccine (CDX-1401 + poly-ICLC) in a nonoverlapping schedule every four weeks with standard-dose decitabine. Results: Analysis of samples serially obtained from the 7 patients who reached the end of the study demonstrated induction of NY-ESO-1 expression in 7 of 7 patients and NY-ESO-1–specific CD4+ and CD8+ T-lymphocyte responses in 6 of 7 and 4 of 7 of the vaccinated patients, respectively. Myeloid cells expressing NY-ESO-1, isolated from a patient at different time points during decitabine therapy, were capable of activating a cytotoxic response from autologous NY-ESO-1–specific T lymphocytes. Vaccine responses were associated with a detectable population of CD141Hi conventional dendritic cells, which are critical for the uptake of NY-ESO-1 vaccine and have a recognized role in antitumor immune responses. Conclusions: These data indicate that vaccination against induced NY-ESO-1 expression can produce an antigen-specific immune response in a relatively nonimmunogenic myeloid cancer and highlight the potential for induced antigen-directed immunotherapy in a group of patients with limited options. Clin Cancer Res; 24(5); 1019–29. ©2017 AACR. See related commentary by Fuchs, p. 991

[1]  M. Goswami,et al.  Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy , 2017, Journal of Translational Medicine.

[2]  M. Goswami,et al.  Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy , 2017, Journal of Translational Medicine.

[3]  S. Baylin,et al.  Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells , 2017, PloS one.

[4]  G. Abel,et al.  Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes , 2016, British journal of haematology.

[5]  P. Fenaux,et al.  Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system , 2016, Haematologica.

[6]  Arash Salmaninejad,et al.  Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers , 2016, Immunological investigations.

[7]  B. Paluch,et al.  Epigenetics: A primer for clinicians. , 2016, Blood reviews.

[8]  U. Germing,et al.  Causes of death in 2877 patients with myelodysplastic syndromes , 2016, Annals of Hematology.

[9]  M. Beckmann,et al.  Abstract B32: Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses , 2016 .

[10]  B. Paluch,et al.  Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy , 2015, Oncotarget.

[11]  Trevor J Pugh,et al.  DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts , 2015, Cell.

[12]  C. Cogle,et al.  Incidence and Burden of the Myelodysplastic Syndromes , 2015, Current Hematologic Malignancy Reports.

[13]  M. Maio,et al.  Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models , 2015, Oncoimmunology.

[14]  M. Treppendahl,et al.  Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation , 2015, Oncotarget.

[15]  M. Nussenzweig,et al.  Restricted dendritic cell and monocyte progenitors in human cord blood and bone marrow , 2015, The Journal of experimental medicine.

[16]  M. Nussenzweig,et al.  Circulating precursors of human CD1c+ and CD141+ dendritic cells , 2015, The Journal of experimental medicine.

[17]  B. Paluch,et al.  Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts , 2015, Epigenetics.

[18]  J. Karbach,et al.  Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts. , 2014, Leukemia research.

[19]  M. Dhodapkar,et al.  Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205 , 2014, Science Translational Medicine.

[20]  N. McGovern,et al.  The evolution of cellular deficiency in GATA2 mutation. , 2014, Blood.

[21]  C. Batt,et al.  Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer , 2014, Cancer Immunology Research.

[22]  S. Parmar,et al.  Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents , 2013, Leukemia.

[23]  Sheng Wei,et al.  Induction of myelodysplasia by myeloid-derived suppressor cells. , 2013, The Journal of clinical investigation.

[24]  C. Braudeau,et al.  Human blood mDC subsets exhibit distinct TLR repertoire and responsiveness , 2013, Journal of leukocyte biology.

[25]  L. Saft,et al.  Bone marrow dendritic cells are reduced in patients with high-risk myelodysplastic syndromes. , 2013, Leukemia research.

[26]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[27]  P. Vyas,et al.  Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). , 2012, Blood.

[28]  C. Bokemeyer,et al.  Cancer‐testis antigen expression and its epigenetic modulation in acute myeloid leukemia , 2011, American journal of hematology.

[29]  H. Kantarjian,et al.  Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. , 2011, Seminars in oncology.

[30]  J. Karbach,et al.  The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. , 2010, Leukemia research.

[31]  P. Vyas,et al.  Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. , 2010, Blood.

[32]  P. Rod Dunbar,et al.  Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens , 2010, The Journal of experimental medicine.

[33]  P. Kloetzel,et al.  Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells , 2010, The Journal of experimental medicine.

[34]  Daniel L. Popkin,et al.  Flt3 permits survival during infection by rendering dendritic cells competent to activate NK cells , 2010, Proceedings of the National Academy of Sciences.

[35]  J. Karbach,et al.  Tumor‐reactive CD8+ T‐cell responses after vaccination with NY‐ESO‐1 peptide, CpG 7909 and Montanide® ISA‐51: association with survival , 2009, International journal of cancer.

[36]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[37]  G. Mufti,et al.  CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). , 2007, Blood.

[38]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[39]  Masato Kato,et al.  Expression of human DEC-205 (CD205) multilectin receptor on leukocytes. , 2006, International immunology.

[40]  A. Hagemeijer,et al.  Circulating myeloid and lymphoid precursor dendritic cells are clonally involved in myelodysplastic syndromes , 2004, Leukemia.

[41]  Yao-Tseng Chen,et al.  NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. , 2003, Cancer research.

[42]  Yao-Tseng Chen,et al.  Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[43]  K. MacDonald,et al.  Characterization of human blood dendritic cell subsets. , 2002, Blood.

[44]  G. Mufti,et al.  Phenotypic and functional characteristics of monocyte‐derived dendritic cells from patients with myelodysplastic syndromes , 1999, British journal of haematology.

[45]  A. Órfão,et al.  Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL , 1999, Leukemia.

[46]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[47]  R. Willemze,et al.  Clonal involvement of granulocytes and monocytes, but not of T and B lymphocytes and natural killer cells in patients with myelodysplasia: analysis by X-linked restriction fragment length polymorphisms and polymerase chain reaction of the phosphoglycerate kinase gene. , 1992, Blood.

[48]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.

[49]  Sebastian Amigorena,et al.  Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity. , 2014, Cancer cell.

[50]  Yao-Tseng Chen,et al.  NY-ESO-1: review of an immunogenic tumor antigen. , 2006, Advances in cancer research.